COMMUNIQUÉS West-GlobeNewswire

InflaRx Announces Participation in September Investor Conferences
20/08/2026
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate [...]
Evaxion announces business update and second quarter 2026 financial results
20/08/2026
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and [...]
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery
20/08/2026
VarmX enrols first participant in global Phase 3 EquilibriX‑S trial evaluating VMX‑C001 in urgent surgery First participant enrolled:  EquilibriX‑S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs [...]
Adagene to Participate in Three Upcoming Investor Conferences
20/08/2026
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based [...]
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
20/08/2026
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 [...]
Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference
20/08/2026
ORANGE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will participate in and attend two upcoming healthcare conferences in New York: Presenting: Baird 2026 [...]
Jushi Holdings Inc. Announces Opening of Relocated Beyond Hello™ Dispensary in Belle Vernon, Pennsylvania
20/08/2026
A Media Snippet accompanying this announcement is available by clicking on this link. BOCA RATON, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ) , a [...]
Frishantic Launches Berberine Supplement with Ceylon Cinnamon for Daily Wellness Routines
20/08/2026
New Formula Combines 500 mg Berberine Hydrochloride with Ceylon Cinnamon, Chromium, Alpha-Lipoic Acid, and BioPerine® NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Frishantic , a supplement brand focused on clean-label [...]
Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan
20/08/2026
Registrations cover the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” [...]
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
20/08/2026
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
20/08/2026
Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working capital obtained to [...]
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
20/08/2026
Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 Sol-Gel has initiated a proof-of-concept [...]
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
20/08/2026
As Commercial and Clinical Programs Advance, RenovoRx Continues to Strengthen its Global Intellectual Property Portfolio with 20 Issued or Allowed Patents and 13 Pending Patents to Support the Commercialization of [...]
Cannabix Technologies Deploys BreathLogix Alcohol System at Montana's Big Horn County Probation and Pre-Trial Services Department Under State's 24/7 Sobriety Program
20/08/2026
VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices, is pleased to announce the deployment of [...]
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
20/08/2026
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”) , a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to [...]
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
20/08/2026
Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
20/08/2026
NANJING, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinical study evaluating [...]
Zelluna ASA: Second Quarter 2026 results
20/08/2026
Oslo, 20 August 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents [...]
Six-month interim report (Q2) 2026 (unaudited)
20/08/2026
ALK delivers 18% organic revenue growth with operating profit (EBIT) up 19% in Q2 ALK sustained strong momentum in Q2, with double-digit growth across all regions driven by sales of tablets and anaphylaxis products. [...]

Pages